Immunovant, Inc. IMVT Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price at other companies
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice.
The official record: Immunovant, Inc.’s 10-Q, filed February 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immunovant, Inc.'s share-based compensation arrangement by share-based payment award, options, exercisable, weighted average exercise price.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immunovant, Inc.'s share-based compensation arrangement by share-based payment award, options, exercisable, weighted average exercise price?
- Immunovant, Inc. (IMVT) reported share-based compensation arrangement by share-based payment award, options, exercisable, weighted average exercise price of $12.32 in Q4 2025.
- How has Immunovant, Inc.'s share-based compensation arrangement by share-based payment award, options, exercisable, weighted average exercise price changed year-over-year?
- Immunovant, Inc.'s share-based compensation arrangement by share-based payment award, options, exercisable, weighted average exercise price increased by 38.1% year-over-year, from $8.92 to $12.32.